Winningham-Major F, Staecker J L, Barger S W, Coats S, Van Eldik L J
Department of Pharmacology, Vanderbilt University, Nashville, Tennessee 37232.
J Cell Biol. 1989 Dec;109(6 Pt 1):3063-71. doi: 10.1083/jcb.109.6.3063.
S100 beta produced in Escherichia coli from a synthetic gene (Van Eldik, L. J., J. L. Staecker, and F. Winningham-Major. 1988. J. Biol. Chem. 263:7830-7837) stimulates neurite outgrowth and enhances cell maintenance in cultures of embryonic chick cerebral cortex neurons. In control experiments, the neurite extension activity is reduced by preincubation with antibodies made against bovine brain S100 beta. When either of the two cysteines in S100 beta are altered by site-directed mutagenesis, the resultant proteins maintain the overall biochemical properties of S100 beta, but lose both the neurite extension and neuronal survival activities. However, another S100 beta mutant, in which the relative position of one of the two cysteines was changed, had neurotrophic activity similar to that of the unmodified protein. These and other results indicate that (a) specific neurite extension activity and neuronal survival activity are two related activities inherent to the S100 beta molecule; (b) a disulfide-linked form of S100 beta is required for full biological activity, and (c) the relative position of the cysteines can be modified. These data suggest potential in vivo roles for S100 beta in the development and maintenance of neuronal function in the central nervous system, and demonstrate the feasibility of the longer term development of selective pharmacological agents based on the S100 beta structure.
由合成基因在大肠杆菌中产生的S100β(范·埃尔迪克,L.J.,J.L.施泰克,和F.温宁厄姆-梅杰。1988年。《生物化学杂志》263:7830 - 7837)可刺激胚胎鸡大脑皮质神经元培养物中的神经突生长并增强细胞维持能力。在对照实验中,用针对牛脑S100β制备的抗体预孵育可降低神经突延伸活性。当通过定点诱变改变S100β中的两个半胱氨酸中的任何一个时,所得蛋白质保持S100β的整体生化特性,但失去神经突延伸和神经元存活活性。然而,另一个S100β突变体,其中两个半胱氨酸之一的相对位置发生了变化,具有与未修饰蛋白质相似的神经营养活性。这些以及其他结果表明:(a)特定的神经突延伸活性和神经元存活活性是S100β分子固有的两种相关活性;(b)S100β的二硫键连接形式是充分生物活性所必需的;(c)半胱氨酸的相对位置可以被修饰。这些数据表明S100β在中枢神经系统神经元功能的发育和维持中具有潜在的体内作用,并证明了基于S100β结构的选择性药理剂长期开发的可行性。